J&J’s Tecvayli Could See More Uptake With Data In Earlier Myeloma Treatment

 
• By Alaric DeArment
  
J&J announced topline results from the MajesTEC-3 trial in relapsed/refractory multiple myeloma patients with one to three prior lines of therapy. (Alaric DeArment)

More from Clinical Trials

More from R&D